Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

Merck & Co. Chief Executive Ken Frazier said a rule to base the price the U.S. government pays for some prescription drugs in Medicare on lower prices in other countries would face legal challenges if adopted.

Read More »

New Klick Health Research: Google Assistant Recognizes Medication Names Better Than Alexa and Siri

Klick Health research found Google Assistant’s comprehension of the most commonly dispensed medication names in the U.S. was, on average, almost twice as accurate as Alexa and Siri’s.

Read More »

Rituxan Superior in Rare, Deadly Skin Disease

Genentech announced positive topline results from the Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug MMF in patients with pemphigus vulgaris.

Read More »

Canada panel calls for universal healthcare system that includes drug coverage

A Canadian advisory council studying prescription drug coverage said the federal government should create a universal, single-payer public pharmacare system, and warned that the current framework requires significant reforms.

Read More »

Merck’s Keytruda wins FDA approval to treat head and neck cancer

Merck & Co. Inc.’s blockbuster cancer drug Keytruda won approval from the U.S. FDA to treat a type of head and neck cancer.

Read More »

The Rebate System Spikes Drug Prices, Scripps Study Confirms

As concerns over the price of prescription medicine continue to make headlines as the country barrels toward another election, a new study from the Scripps Research bolsters an argument touted by the pharmaceutical industry over the rebate system.

Read More »

Five-Year Survival Observed In Longest Follow-Up Of Advanced Melanoma Patients Treated With Opdivo-Yervoy Combination

Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.

Read More »

Merck’s Keytruda sets new five-year survival standard for advanced lung cancer

Nearly a quarter of patients who received Merck & Co.’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting.

Read More »

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

Novartis released data showing sharply improved overall survival rates for the breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer’s blockbuster Ibrance.

Read More »

British Columbia to be first Canadian province to switch patients to biosimilars

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom